SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ZYUS Life Sciences Corporation (the "Company") (TSXV:ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced that it has launched a brokered private placement of a minimum of 23,809,523 units of the Company (each a "Unit") and up to a maximum of 25,396,825 Units, at a price of C$0.63 per Unit (the "Offering Price"), for minimum gross proceeds of C$15,000,000 and maximum gross proceeds of up to C$16,000,000 (the "LIFE Offering").
Each Unit will be comprised of one common share of the Company (each, a "Common Share") and one-half (½) of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder to purchase one additional Common Share (a "Warrant Share") at an exercise price of C$0.85 for a period of 24 months from the date of issuance.
The LIFE Offering will be conducted on a best-efforts, fully marketed basis by Canaccord Genuity Corp., acting as sole lead agent and sole bookrunner (the "Lead Agent"), on behalf of a syndicate of agents to be formed (collectively with the Lead Agent, the "Agents").
In connection with the LIFE Offering, the Company has agreed to pay the Agents a cash commission of 5.0% of the gross proceeds of the LIFE Offering, and to issue Agents' warrants equal to 5.0% of the number of Units sold under the LIFE Offering, each Agents' warrant exercisable for one Common Share at the Offering Price for a period of 36 months from the date of issuance. Subscriptions from purchasers on the President's List up to a maximum of C$5,000,000 will be subject to reduced compensation of 2.5% cash commission and 2.5% Agents' warrants. In addition, the Company will pay the Lead Agent a corporate finance fee consisting of (i) a cash fee equal to 2.0% of the gross proceeds of the LIFE Offering and (ii) corporate finance warrants equal to 2.0% of the number of Units sold under the LIFE Offering, in each case excluding President's List subscriptions.
The net proceeds of the LIFE Offering will be used to advance the ongoing clinical development of the Company's lead drug candidate, Trichomylin® softgel capsules, including completion of the Company's Phase 2a clinical trial and ...
